Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Novavax and Vivalis, a biopharmaceutical company, have completed a research license to use the Vivalis EB66 cell line, for the production of Novavax virus like particle based vaccines.
Subscribe to our email newsletter
Through this collaboration, Novavax intends to test the EB66 cell line for the production of virus like particle (VLP) vaccines against several new potential viruses.
Rahul Singhvi, CEO of Novavax, said: “Novavax is delighted to have the opportunity to evaluate the EB66 cell line for its potential use with our new VLP targets.
“This collaboration is consistent with our manufacturing strategy to use scalable cell culture solutions for production of recombinant VLP vaccines and increases our flexibility to design, develop and manufacture such vaccines to address significant unmet medical needs.”